United States · Platforms & data · MarketBeat

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Published by MarketBeat · United States 1 h ago

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

Is Berkshire Bending the Rules With Bending Spoons?

Seeking Alpha

Musk says Ukraine violated Starlink terms with offensive drone strikes

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Investing.com

Lula, Bolsonaro rally supporters on final day before Brazil presidential runoff

Yahoo Finance

First Interstate BancSystem: 3 Key Takeaways for Long-Term Investors

TheStreet